Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | PMC:PMC10933946 | DOI:10.3390/jcm13051520
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Infectious Diseases | Lung Cancer | Meningitis Vaccine | Non-Small Cell Lung Cancer | Pneomococcal Vaccine | Study | Vaccines